Replacement therapy with clotting factor concentrates is the most common treatment for people with hemophilia A or hemophilia B. While there have been advances in the treatment options for people with hemophilia, there remains a need for additional prophylactic non-factor therapy options, especially for people with hemophilia B with and without inhibitors. This program will provide information on a prophylactic treatment option for people with hemophilia B and hemophilia A with and without inhibitors and share results from clinical trials.